Loading clinical trials...
Loading clinical trials...
Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.
Conditions
Interventions
TMC435350; Placebo
Start Date
January 1, 2007
Primary Completion Date
September 1, 2007
Completion Date
September 1, 2007
Last Updated
May 19, 2011
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions